Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

Niall Martin, Chief Executive Officer
+44 01223 867 867 Media & IR Enquiries
Optimum Strategic Communications?
Mary Clark/?Eva Haas/?Manel Mateus
artios@optimumcomms.com
+44 020 3922 1906 Merck KGaA, Darmstadt,?Germany
Gangolf Schrimpf, Media Relations
gangolf.schrimpf@merckgroup.com
+49 6151 72-9591 Notes to Editors About Artios Pharma Ltd. Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. ?The Company, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR),?London, the Netherlands Cancer Institute (NKI) and the National Centre for Biomolecular Research at Masaryk University in the?Czech Republic, with their expertise in DNA repair nucleases. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers. It is backed by blue chip investors including: AbbVie Ventures, Andera Partners (formerly EdRIP), Arix Bioscience plc, IP Group plc, LSP, M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in?Cambridge, UK, with offices in?New York City, USA.?www.artiospharma.com About Merck KGaA, Darmstadt,?Germany Merck KGaA, Darmstadt, Germany,?a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices ? the company is everywhere. In 2019, Merck KGaA, Darmstadt,?Germany?generated sales of ? 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck KGaA, Darmstadt,?Germany's?technological and scientific advances. This is how Merck KGaA, Darmstadt,?Germany?has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck KGaA, Darmstadt,?Germany?holds the global rights to the Merck KGaA, Darmstadt,?Germany?name and brand. The only exceptions are?the United States?and?Canada, where the business sectors of Merck KGaA, Darmstadt,?Germany?operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. SOURCE Artios Pharma